Nature Cancer, Published online: 09 September 2026; doi:10.1038/s43018-026-01229-9

Lai et al. show that Nakaseomyces glabratus is enriched in fecal and tumor samples of patients with castration-resistant prostate cancer and that administration of the fungus accelerates cancer progression in prostate cancer-bearing castrated mice.

Nature Cancer, Published online: 01 September 2026; doi:10.1038/s43018-026-01231-1

The addition of oral l-glutamine to first-line gemcitabine plus nab-paclitaxel appears safe and is associated with improved survival outcomes and tumor responses compared with historical benchmarks in untreated advanced pancreatic cancer. The beneficial effects of l-glutamine may be mediated through modulation of intermediary metabolism, gut microbial function, inflammatory responses and gut barrier integrity.

Nature Cancer, Published online: 01 September 2026; doi:10.1038/s43018-026-01243-x

Publisher Correction: Adjuvant personalized multivalent neoantigen DNA vaccination for MGMT unmethylated glioblastoma: a phase 1 trial

Nature Cancer, Published online: 01 September 2026; doi:10.1038/s43018-026-01220-4

Chen et al. have developed SlideChat, a multimodal generative artificial intelligence assistant, which they benchmark on 27 pathology tasks across 33 cancer types. Expert pathologists rated the assistant as clinically relevant and accurate.

Nature Cancer, Published online: 31 August 2026; doi:10.1038/s43018-026-01225-z

In this open-label, single-arm, phase 1 GlutaPanc trial, Gong and colleagues report the safety and feasibility of l-glutamine in participants with advanced pancreatic ductal adenocarcinoma and determine the recommended phase 2 dose of l-glutamine in combination with gemcitabine and nab-paclitaxel.

Nature Cancer, Published online: 25 August 2026; doi:10.1038/s43018-026-01241-z

Author Correction: Low-protein diet enhances antitumor immunity in pancreatic cancer through microbiota-derived UDP-galactose

Nature Cancer, Published online: 25 August 2026; doi:10.1038/s43018-026-01221-3

Chen and colleagues report that the neuropeptide galanin impairs antitumor immunity in glioblastoma by interacting with its receptor GALR3 on monocytic myeloid-derived suppressor cells, promoting their infiltration and ferroptosis resistance.

Nature Cancer, Published online: 21 August 2026; doi:10.1038/s43018-026-01219-x

Paul Mischel obtained his MD from Cornell University Medical College, trained in anatomic and neuropathology at UCLA and did post-doctoral research training in Louis Reichardt’s lab at HHMI/UCSF. He is the Fortinet Founders Professor, vice chair for research for the department of pathology, and deputy director of translational science and an institute scholar at Sarafan ChEM-H, Stanford University. Mischel leads Team eDyNAmiC of the Cancer Grand Challenges Program. He is a member of the National Academy of Medicine, a fellow of the AACR Academy, and past president of the American Society for Clinical Investigation.